About Genmab A/SGenmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX™ (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.
CEO and Founder: Jan G. J. van de Winkel, Ph.D.
CFO: David Eatwell
JOBS: Please click here for Genmab job opportunities.
Please click here for clinical trial information.
FOLLOW GENMAB: Tweets by Genmab
357 articles with Genmab A/S
Genmab A/S Announces Positive Topline Results In Phase III ALCYONE Study Of Daratumumab In Front Line Multiple Myeloma
Genmab A/S Announces European Marketing Authorization For DARZALEX (Daratumumab) For Relapsed Or Refractory Multiple Myeloma
Grant Of Restricted Stock Units To Two New Board Members And Grant Of Restricted Stock Units And Warrants To The New Member Of Management In Genmab A/S
Constitution Of The Board Of Directors In Genmab A/S And Grant Of Restricted Stock Units And Warrants To Employees In Genmab
Genmab A/S Achieves USD 25 Million Sales Milestone In DARZALEX (Daratumumab) Collaboration With Janssen Pharmaceutica N.V.
Genmab A/S Announces Submission Of Regulatory Application For Daratumumab In Relapsed/Refractory Multiple Myeloma In Japan And Updates Financial Guidance
Genmab A/S Announces U.S. FDA Approval Of DARZALEX (Daratumumab) For Relapsed Multiple Myeloma And Updates Financial Guidance
Genmab A/S Announces Phase III Study Of Daratumumab In Combination With Carfilzomib In Multiple Myeloma